Cellular G-protein-linked signalling protein. The protein is also referred to as p21ras. It is a proto-oncogene in that the wild-type protein product serves a physiological role, but mutations result in an oncogene due to inappropriate celllular signalling.
K-ras is mutated in ~40% of colorectal cancers, most frequently with point mutation at codons 12, 13 and 61. In patients with activating mutations of k-ras, upstream inhibition of EGFR signalling by cetuximab, panitumumab, gefitinib and erlotinib may be ineffective.
- ↑ Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. Journal of the National Cancer Institute. 1967 Aug; 39(2):311-35.
- ↑ Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987 May 28-Jun 3; 327(6120):293-7.(Link to article – subscription may be required.)